Towards targeted removal of
treatment-resistant cells
Celluminova specializes in developing innovative technologies designed to detect cancer stem cells. Our ambition is to make these highly invasive and treatment-resistant cells visible, opening new possibilities for how they can be addressed. Our initial indication is high-grade gliomas, including glioblastoma.
Serious science. Shared purpose.
Celluminova grew out of years of persistent research and a shared ambition to make a difference for patients with aggressive brain tumors. Today, we are a small, dedicated team combining scientific rigor with a strong sense of responsibility for the technology we are developing.
From p-HTMI to GlioStem® Surgery
p-HTMI is the core molecule underlying our technology and forms the basis of our product candidate, GlioStem® Surgery, which is being developed as an intraoperative imaging agent for glioma surgery.
